Co-Occurring Behavioral Health Disorders

These reports and detailed tables present estimates from the 2019 National Survey on Drug Use and Health (NSDUH), specifically pertaining to substance use among women.

SAMHSA offers evidence-based resources to help providers screen, diagnose, and deliver integrated care to patients with co-occurring disorders.

The following checklist intends to support health care teams in providing evidence-based recommendations for treating pregnant and postpartum patients with OUD. The checklist is divided into five sections, sequenced by timing of presentation to care.

This toolkit provides tools to both providers and patients for the assessment and management of perinatal mood and anxiety disorders, as well as substance use disorders (SUD).

This document summarizes a discussion from a workshop where experts examined the evidence for candidate endpoints and study design strategies for clinical trials of stimulant use disorder treatments.

This was a virtual public workshop to discuss a practical research agenda toward treatment development for stimulant use disorder. Meeting participants responded to a proposed practical research agenda that focuses on innovation in clinical trial design and candidate endpoints for the evaluation of potential treatments for stimulant use disorder.

This two-day public workshop convened regulators, academic researchers, clinicians, patient advocates, and other stakeholders to share information underlying this action and gather input related to the safe use of benzodiazepines.

The Helping to End Addiction Long-term Initiative, or NIH HEAL Initiative, is an aggressive, trans-agency effort to speed scientific solutions to stem the national opioid public health crisis.

This was a two-day virtual public workshop (which can now be re-watched) that focused on identifying gaps in existing opioid prescriber education offerings and core competencies that should be included in educational content for opioid prescribers and other healthcare providers, including prescriber education under a Risk Evaluation and Mitigation Strategy (REMS).

This was a two-day virtual public workshop (which can now be re-watched) that convened regulators, clinical researchers, providers, patient advocates, and other stakeholders to exchange information and obtain input by discussing prescriber education's potential role in alleviating the evolving opioid and substance use crisis.